2Slides Logo
Preview

Mesoblast ASX Investor Day Presentation November 2026

20 slides

Part of Investor presentation examples · Australian investor presentation examples

Mesoblast ASX Investor Day Presentation November 2026 — Mesoblast Ltd's (ASX: MSB; Nasdaq: MESO) 20-slide CEO presentation at the ASX Investor Day, lodged with the ASX on November 15, 2026. It covers FY2026 results from the first year of the U.S. commercial launch of RYONCIL (remestemcel-L-rknd), including net revenue of US$115M. It also covers the company's IP and manufacturing moat, its allogeneic mesenchymal stromal cell pipeline, the adult SR-aGvHD label-extension trial, the rexlemestrocel-L Phase 3 chronic low back pain program, heart failure and Group 2 pulmonary hypertension opportunities, and the next major milestones.

7 likes
0 downloads

Uses this deck’s cover as a style reference for slides made from your own content. Or pick any page below to use its layout as the reference.

Quick Navigation

Tags

Mesoblast
MSB
MESO
ASX Investor Day
Investor presentation

Share the slides

Description

Main Topic

Mesoblast ASX Investor Day Presentation November 2026 — Mesoblast Ltd's (ASX: MSB; Nasdaq: MESO) 20-slide CEO presentation at the ASX Investor Day, lodged with the ASX on November 15, 2026. It covers FY2026 results from the first year of the U.S. commercial launch of RYONCIL (remestemcel-L-rknd), including net revenue of US$115M. It also covers the company's IP and manufacturing moat, its allogeneic mesenchymal stromal cell pipeline, the adult SR-aGvHD label-extension trial, the rexlemestrocel-L Phase 3 chronic low back pain program, heart failure and Group 2 pulmonary hypertension opportunities, and the next major milestones.

Key Benefits

  • •FY2026 headline financials in US$: net revenue US$115M and gross profit, excluding amortization, of US$110M
  • •Stated milestone timing: adult SR-aGvHD interim analysis expected Q4 CY2027, CLBP Phase 3 readout H2 CY2027, and potential CLBP approval in CY2028
  • •Full LVAD II trial table of major mucosal bleeding rates with nominal p-values
  • •A U.S. patient funnel for Group 2 pulmonary hypertension: 6.5M heart failure patients narrowing to a ~1.1M potential target population
  • •Pipeline chart with total addressable market estimates for each program (~US$1B, >US$1B, >US$10B, >US$10B)
  • •Commercial metrics for RYONCIL: >50 centers onboarded, 98% of US lives covered and a J-code obtained

Target Audience

  • •ASX and Nasdaq retail and institutional investors in Mesoblast (MSB / MESO)
  • •Biotech and cell-therapy equity analysts
  • •Healthcare portfolio managers following regenerative medicine
  • •Business development and partnering teams in cardiology, pain and transplant medicine
  • •Industry researchers tracking allogeneic MSC therapies and FDA approvals

Use Cases

  • •Reviewing Mesoblast's FY2026 commercial performance after the RYONCIL launch
  • •Tracking catalyst timelines for the CLBP, adult SR-aGvHD and LVAD/heart failure BLA programs
  • •Sizing the market for rexlemestrocel-L in Group 2 pulmonary hypertension and heart failure
  • •Comparing cell-therapy pipeline maturity and TAM claims across peers
  • •Preparing investor notes or valuation models on MSB/MESO

Unique Value Propositions

  • •RYONCIL is positioned as the first and only MSC therapy approved by the FDA
  • •Global IP portfolio of >1,100 patents and patent applications, with protection through >2044
  • •Assets are wholly owned and unencumbered in U.S. markets; JCR, Grünenthal and Tasly hold specified regional rights
  • •The deck says FDA has agreed the BLA filing may proceed for rexlemestrocel-L in LVAD patients with life-threatening major GI bleeding
  • •A single mechanism of action, reducing inflammation and reversing endothelial dysfunction, underpins several cardiopulmonary label-extension opportunities

Slide Pages (20)

Detailed view of each slide page, including layout, key content and visual elements.

Page 1
Title / Cover

Global Leader in Allogeneic Cellular Medicines for Inflammatory Diseases — ASX Investor Day

Content

This is the cover slide, which positions Mesoblast as a global leader in allogeneic cellular medicines for inflammatory diseases. It is dated November 2026 and gives the tickers ASX: MSB and Nasdaq: MESO.

Layout Structure

Split layout: a patient photo in a leaf-shaped frame on the left, with the logo, title and subtitle on the right

Key Visual Elements

  • •Mesoblast logo
  • •Photo of an adult embracing a child in a leaf-shaped frame
  • •Dotted divider
  • •Ticker and date caption
Page 2
Disclaimer / Legal

Cautionary Note Regarding Forward Looking Statements

Content

This is a standard safe-harbor disclaimer under the Private Securities Litigation Reform Act of 1995. It lists risks including clinical trial and regulatory uncertainty, manufacturing scalability, intellectual property, partner relationships and the need for future capital. Readers are referred to the company's SEC filings.

Layout Structure

Single full-width block of justified text below the title

Key Visual Elements

  • •Dense paragraph text
  • •Branded footer bar with page number
Page 3
Financial Highlights

FY2026: Highlights for the Year and Delivery of Major Milestones

Content

In the first year of the U.S. commercial launch of RYONCIL, FY2026 net revenue was US$115M and gross profit on total sales, excluding amortization expense, was US$110M. Milestones achieved: 350 patients treated in the Phase 3 chronic low back pain (CLBP) trial; alignment with FDA on filing for approval in end-stage heart failure; an adult SR-aGvHD label-extension registration trial now enrolling, targeting 40 U.S. sites; and FDA clearance of the IND for a pediatric Duchenne Phase 3 trial. The company also entered a US$125.0 million five-year non-dilutive credit facility that consolidates and retires two higher-cost facilities.

Layout Structure

Two-section bullet and checklist on the left, with a product vial image and RYONCIL logo on the right

Key Visual Elements

  • •RYONCIL (remestemcel-L-rknd) logo
  • •Product vial photo
  • •Checkmark milestone list
  • •Cyan section headers
Page 4
Competitive Advantage

Our 'MOAT' – Our Market Leadership Position

Content

Mesoblast lists its competitive advantages. Its global IP portfolio of >1,100 patents and patent applications provides protection through >2044, and RYONCIL is described as the first and only MSC approved by FDA. Further claims cover the use of FDA guidance for label extensions, large completed U.S. randomized trials, leadership in cell manufacturing, next-generation tissue-homing technology, and an experienced executive team.

Layout Structure

Single-column checklist of eight items

Key Visual Elements

  • •Cyan checkmarks
  • •Large-type bullet statements
  • •Abbreviation footer
Page 5
Business Overview

Mesoblast First-In-Class Leader in Allogeneic Cellular Therapies

Content

The slide has three pillars. First, Ryoncil, the only FDA-approved MSC: net revenue of US$115M in FY2026, its first full year post launch, described as highly profitable on a stand-alone basis, with opportunities in adult aGvHD and pediatric inflammatory diseases such as Duchenne muscular dystrophy. Second, commercial capability: >50 centers onboarded, 98% of US lives covered and a J-code obtained. Third, rexlemestrocel-L as the engine for blockbuster opportunities in chronic low back pain and pulmonary hypertension in left heart failure.

Layout Structure

Three columns, each with an icon tile, heading and supporting text

Key Visual Elements

  • •Growth chart icon
  • •People network icon
  • •Hand-with-sprout icon
  • •Dashed horizontal divider
Page 6
Pipeline

Mesoblast Worldwide Leader Allogeneic Mesenchymal Stromal Cell Portfolio

Content

The pipeline chart covers assets wholly owned and unencumbered in U.S. markets. RYONCIL is approved for pediatric SR-aGvHD and is in development for adult SR-aGvHD and Duchenne's. Rexlemestrocel-L (STRO3+) is in development for end-stage adult HFrEF, Class II/III HFrEF, pulmonary hypertension and CLBP. The chart states TAMs of ~US$1B (SR-aGvHD), >US$1B (Duchenne's), >US$10B (cardiopulmonary) and >US$10B (CLBP). Notes state that JCR holds certain Japanese MSC rights, Grünenthal licenses CLBP rights in Europe and Latin America/Caribbean, and Tasly holds chronic heart failure rights in China. The chart is labelled figurative.

Layout Structure

Pipeline table with Product, Indication, Phase 2, Phase 3 and Approved columns, progress bars, TAM circles on the right, and footnotes

Key Visual Elements

  • •Gradient progress bars with chevrons
  • •Yellow bar marking approved indication
  • •Blue and green TAM circles
  • •Partner footnotes
Page 7
Section Divider

RYONCIL — Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)

Content

This section divider introduces the RYONCIL program in steroid-refractory acute graft versus host disease.

Layout Structure

Section divider: photo in an orange leaf-shaped frame on the left, with the title on the right

Key Visual Elements

  • •Photo of mother and child in hospital
  • •Orange frame accent
  • •Dotted divider
Page 8
Clinical Trial Design

Potential Market for RYONCIL Label Extension as Part of Second-line Regimen Combined with Ruxolitinib in Adults with Grade III/IV aGvHD

Content

More than 2,000 U.S. adults have SR-aGvHD each year, and ~50% of them have Grade III/IV disease. The registration trial randomizes 180 Grade III/IV SR-aGvHD adults 1:1 to ruxolitinib or ruxolitinib + RYONCIL. The primary endpoint is Day 28 overall response and the secondary endpoint is Day 180 overall survival. The trial targets ~40 U.S. centers, representing >50% of annual allo transplants, and is expected to last 18-24 months. An interim analysis is planned when the first 102 patients (57% enrolled) reach Day 28, and is expected in Q4 CY2027.

Layout Structure

Bullet list on top, with a dark blue banner below containing a pie chart and the interim-analysis callout

Key Visual Elements

  • •Pie chart showing 57%
  • •Dark navy callout band
  • •Bullet list
Page 9
Section Divider

Rexlemestrocel-L — Chronic Low Back Pain due to Degenerative Disc Disease (CLBP)

Content

This section divider introduces the rexlemestrocel-L program in chronic low back pain due to degenerative disc disease.

Layout Structure

Section divider: photo in a blue leaf-shaped frame on the left, with the title on the right

Key Visual Elements

  • •Photo of person holding lower back
  • •Blue frame accent
  • •Dotted divider
Page 10
Clinical Program / Milestones

Phase 3 trial to Reduce Inflammation & Pain in Degenerative Disc Disease

Content

The slide describes targeted, minimally invasive delivery of rexlemestrocel-L to the degenerated disc. It lists four milestones to commercial launch: the P3 trial is fully enrolled with 350 patients; the primary endpoint is 12-month pain reduction and the secondary endpoint is improved function; trial readout is expected in H2 CY2027, followed by a BLA filing; and potential approval in CY2028.

Layout Structure

Left: anatomical illustration of a healthy versus degenerative disc with a delivery catheter. Right: a numbered milestone list.

Key Visual Elements

  • •Side-by-side disc anatomy illustration
  • •Delivery catheter graphic
  • •Healthy vs degenerated disc comparison boxes
  • •Numbered milestone circles
Page 11
Market Opportunity

The Patient Treatment Journey

Content

About 7M US patients have moderate to severe degenerative disc disease within 5 years of diagnosis that is refractory to medical therapies, including opioids. The treatment pathway runs from conservative treatments (NSAIDs, physical therapy, chiropractic, acupuncture, anticonvulsants) to opioid analgesics, interventional therapies (epidural steroid injections, radiofrequency ablation, spinal cord stimulation, intrathecal pumps) and then surgery (spinal fusion, disc replacement). Rexlemestrocel-L targets moderate-to-severe CLBP, positioned across the opioid and interventional stages.

Layout Structure

Four color-coded columns representing treatment stages, with a bracket above the middle two columns

Key Visual Elements

  • •Four color-blocked treatment columns
  • •Bracket annotation
  • •Navy, periwinkle, black and orange palette
Page 12
Section Divider

Rexlemestrocel-L — Heart Failure

Content

This section divider introduces the rexlemestrocel-L heart failure program.

Layout Structure

Section divider: photo in a teal leaf-shaped frame on the left, with the title on the right

Key Visual Elements

  • •Photo of hands on chest
  • •Teal frame accent
  • •Dotted divider
Page 13
Mechanism of Action / Pipeline Strategy

Cardiopulmonary Indications Leveraging Rexlemestrocel-L Mechanism

Content

The slide argues that an LVAD BLA approval could open label-extension potential in two further blockbuster indications with the same mechanism. Three indications are shown: end-stage HFrEF with LVAD (159-patient LVAD trial: reduction in major GI bleeding and RV dysfunction); NYHA Class II/III HFrEF (565-patient DREAM-HF trial: reduction in cardiac death, MI and stroke); and Group 2 pulmonary hypertension (DREAM-HF: improved diastolic function, pulmonary hypertension and survival). The common mechanism is a reduction in M1 macrophage and T-cell burden (IL-1β, IL-6, IL-12, IFN-γ), improved endothelial/NO signaling, and improved LV, pulmonary arterial and RV function.

Layout Structure

Three teal header cards on top, with arrows pointing up from a mechanism-of-action box at the bottom

Key Visual Elements

  • •Heart icons
  • •Teal indication cards
  • •Upward arrows
  • •Outlined mechanism box
Page 14
Clinical Data

Rexlemestrocel-L Reduces GI Bleeding in End-stage HFrEF Patients with LVADs by Reversing Endothelial Dysfunction of GI Blood Vessels Due to Inflammation

Content

LVAD II 6-month major mucosal bleeding events (MMBE rate per 100 patient months), control versus rexlemestrocel-L: all subjects (N=159) 15.6 vs 3.8 (p<0.0001); destination therapy (n=59) 20.4 vs 2.5 (p=0.0007); bridge to transplant (n=100) 12.9 vs 4.6 (p=0.0172), all nominal p-values. Mesoblast plans to file with FDA for full approval in patients with LVADs. Major GI bleeding is an FDA-acknowledged indication for which rexlemestrocel-L has Orphan Drug designation, and FDA confirmed that the BLA filing may proceed for patients with life-threatening major GI bleeding.

Layout Structure

Data table at the top center, with three bullets below

Key Visual Elements

  • •Four-column results table
  • •Teal table caption
  • •Bullet list
Page 15
Disease Background

Group 2 Pulmonary Hypertension (Due to LV Dysfunction)

Content

The slide explains how left-heart disease raises pulmonary pressure and right ventricular load. LV or valve disease raises left atrial pressure, the pressure backs up into the lung veins and capillaries, and the higher pulmonary pressure increases RV afterload.

Layout Structure

Three-step left-to-right process diagram with illustrations and captions

Key Visual Elements

  • •Anatomical heart illustrations
  • •Lung vasculature illustration
  • •Blue process arrows
Page 16
Clinical Data

Rexlemestrocel-L Improved Survival in HFrEF with Group 2 Pulmonary Hypertension in DREAM-HF Trial

Content

In DREAM-HF, 219 HFrEF patients had established Group 2 pulmonary hypertension, defined as PASP >35 mmHg. A single intra-cardiac injection improved LV diastolic function measured by Doppler echocardiography and reduced Left Atrial Volume Index over 36 months. It also reduced cardiac mortality by 53% in HFrEF patients with Type 2 PH and active inflammation, defined as CRP >2 mg/L (p=0.036).

Layout Structure

Text-only slide with four bullets

Key Visual Elements

  • •Bullet list
  • •Grey headline text
Page 17
Market Opportunity / TAM

Group 2 PH: A Large Unmet Need with No Approved Drugs

Content

Group 2 PH is the most common PH group, at approximately 40% of left-sided heart failure, and no drugs currently used for HFrEF or HFpEF have any effect on it. The illustrative U.S. patient funnel shows 6.5M total heart failure patients (3.0M HFrEF, 3.5M HFpEF). Of these, ~35% have sPAP >35 mmHg (1.05M HFrEF, 1.225M HFpEF), and ~50% of those have CRP ≥2 (0.5M HFrEF, 0.6M HFpEF). That gives a potential target population of ~1.1M patients.

Layout Structure

Left: clinical-context card with star bullets. Right: three-tier funnel inside a bordered panel.

Key Visual Elements

  • •Inverted funnel graphic
  • •Star bullet icons
  • •Highlighted target-population callout
Page 18
Section Divider

In Summary

Content

This section divider introduces the closing summary.

Layout Structure

Section divider: photo in a light-blue leaf-shaped frame on the left, with the title on the right

Key Visual Elements

  • •Cover photo repeated
  • •Dotted divider
Page 19
Summary / Roadmap

Summary of Major Milestones

Content

There are three workstreams. (1) Commercial and label expansion for RYONCIL: grow the pediatric SR-aGvHD revenue base, complete the adult second-line Grade III/IV registration trial, and extend into pediatric inflammatory rare diseases including Duchenne; the adult SR-aGvHD market is described as ~3x the pediatric market. (2) The CLBP blockbuster program: patient treatment in the pivotal Phase 3 was completed in August, follow-up continues through 12 months, and trial completion is targeted for mid-CY2027, followed by a BLA filing. (3) The heart failure blockbuster program: complete the BLA for end-stage heart failure patients on LVADs, pursue label extensions into PH and NYHA II/III HFrEF, and seek a cardiopulmonary strategic alliance.

Layout Structure

Three-column card layout with colored top bars, numbered circles, stage tags and a bottom callout box in each column

Key Visual Elements

  • •Orange, navy and teal column accents
  • •Stage tags (GROW, EXPAND, EXTEND, COMPLETED, READOUT, FILE, PARTNER)
  • •Vertical connector lines
  • •Outlined callout boxes
Page 20
Closing

Thank You

Content

This is the closing slide, with the Mesoblast logo and a thank-you message.

Layout Structure

Photo in a leaf-shaped frame on the left, with the logo and 'Thank You' on the right

Key Visual Elements

  • •Mesoblast logo
  • •Cover photo
  • •Dotted divider

Frequently Asked Questions

Common questions about this slide and the underlying presentation content.

What is the Mesoblast ASX Investor Day Presentation November 2026?

It is a 20-slide CEO presentation that Mesoblast Ltd (ASX: MSB, Nasdaq: MESO) gave at the ASX Investor Day and lodged with the ASX on November 15, 2026. It reviews FY2026 performance, the RYONCIL launch, the rexlemestrocel-L pipeline and upcoming milestones.

How much revenue did Mesoblast report for FY2026?

The deck reports FY2026 net revenue of US$115M, the first full year after RYONCIL's U.S. launch. It reports gross profit on total sales, excluding amortization expense, of US$110M. All figures are in US dollars.

What period does FY2026 cover for Mesoblast?

Mesoblast's fiscal year ends June 30, so FY2026 runs from July 1, 2025 to June 30, 2026. Calendar-year milestones in the deck are labelled CY, for example Q4 CY2027 and CY2028.

When are the key upcoming catalysts?

The deck expects an interim analysis of the adult SR-aGvHD trial in Q4 CY2027. For CLBP, slide 10 gives a Phase 3 readout in H2 CY2027 followed by a BLA filing, and slide 19 targets trial completion for mid-CY2027; potential CLBP approval is CY2028. It also plans a BLA filing for rexlemestrocel-L in end-stage heart failure patients on LVADs.

What clinical data does the deck present for rexlemestrocel-L in LVAD patients?

In LVAD II, the 6-month rate of major mucosal bleeding events per 100 patient months was 15.6 for control versus 3.8 for rexlemestrocel-L across all 159 subjects (nominal p<0.0001). Results are also shown for the destination therapy and bridge to transplant subgroups.

How large is the market opportunity Mesoblast describes?

The pipeline slide shows TAMs of ~US$1B for SR-aGvHD, >US$1B for Duchenne's, and >US$10B each for the cardiopulmonary indications and chronic low back pain. The Group 2 pulmonary hypertension funnel estimates a U.S. target population of ~1.1M patients.

What is RYONCIL and why is it significant?

RYONCIL (remestemcel-L-rknd) is Mesoblast's allogeneic mesenchymal stromal cell therapy for pediatric steroid-refractory acute graft versus host disease. The deck describes it as the first and only MSC approved by the FDA, with >50 centers onboarded, 98% of US lives covered and a J-code obtained.

Who should download this deck?

Investors, biotech analysts and industry professionals tracking Mesoblast, allogeneic cell therapy, or treatments for chronic low back pain, heart failure and graft versus host disease. They will find a short summary of FY2026 results, the pipeline and catalyst timelines.

2slides

Create Your Own Slides

Turn your ideas into professional presentations in seconds with 2slides AI.

Create World-Class Slides in Seconds

Reference professional designs, choose your style, and generate slides with perfect text rendering. Powered by Nano Banana—start creating your presentation now.

2Slides logo

Your AI Agent for slides. Save time, shine faster with intelligent presentation creation.

Summarize with AI

ChatGPTClaudeGrokPerplexity
All services online

© 2026 2slides. All rights reserved.